- Home
- GLUE vs TASK Comparison
GLUE vs TASK Comparison
Compare GLUE & TASK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | TASK |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLUE | TASK |
|---|---|---|
| Price | $16.03 | $11.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.50 | $17.20 |
| AVG Volume (30 Days) | ★ 976.6K | 284.8K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | 0.25 | ★ 0.88 |
| Revenue | $181,538,000.00 | ★ $1,144,833,000.00 |
| Revenue This Year | $81.52 | $20.40 |
| Revenue Next Year | N/A | $7.85 |
| P/E Ratio | $62.71 | ★ $12.99 |
| Revenue Growth | ★ 1112.27 | 19.88 |
| 52 Week Low | $3.50 | $10.68 |
| 52 Week High | $19.17 | $18.59 |
Technical Indicators
Market Signals| Indicator | GLUE | TASK |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 39.44 |
| Support Level | $14.64 | $11.40 |
| Resistance Level | $19.17 | $12.65 |
| Average True Range (ATR) | 1.23 | 0.34 |
| MACD | -0.29 | 0.02 |
| Stochastic Oscillator | 30.91 | 12.40 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.